influenza vaccine (h5n1) (split virion, inactivated, adjuvanted)

The H5N1 adjuvanted split virus vaccine (GSK1562902A) is a monovalent, inactivated, split-virion influenza vaccine developed by GSK. It is formulated with the proprietary oil-in-water emulsion adjuvant AS03, which significantly enhances the immune response and allows for a reduced antigen dose (3.75–3.8 µg), a critical feature for maximizing vaccine supply during a pandemic. The vaccine is derived from the A/Vietnam/1194/2004 (H5N1) strain and is indicated for active immunization against the H5N1 subtype of influenza A virus in pre-pandemic or pandemic situations. It has received regulatory approval in Europe under the brand names Prepandrix (for pre-pandemic use) and Adjupanrix (for pandemic use), and in the United States as Q-Pan H5N1. Clinical studies have demonstrated its ability to induce high levels of neutralizing antibodies and provide cross-reactive immunity against heterologous H5N1 strains.

Brand names

PrepandrixAdjupanrixQ-Pan H5N1

Other names

H5N1 adjuvanted split virus vaccineH-5N1 adjuvanted split virus vaccineH 5N1 adjuvanted split virus vaccineAS03-adjuvanted H5N1 vaccineAS-03-adjuvanted H5N1 vaccineAS 03-adjuvanted H5N1 vaccineGSK H5N1 pandemic influenza vaccine